9 completed, 1 recruiting. 7 Phase 1, 3 Phase 2.
By phase and status
Follow NNC0519-0130: new trials by email Literature Review of NNC0519-0130 trials Research Report on NNC0519-0130
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
A Research Study of the New Medicine NNC0519-0130 in Male Chinese Participants Living With Excess Body Weight NNC0519-0130, Placebo - Diabetes Mellitus, Type 2, Obesity Phase 1 Completed 20 2025-05-26 2026-03-31
A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease NNC0519-0130, Placebo, Semaglutide - Chronic Kidney Disease Phase 2 Recruiting 465 2024-12-02 2026-03-11
A Research Study Comparing Different Ways of Increasing the Dose of NNC0519-0130 in Participants With Overweight or Obesity NNC0519-0130 - Obesity Phase 1 Completed 134 2024-11-20 2026-04-03
A Research Study of How Safe a New Medicine Called NNC0519 0130 is and to Test Its Effect in People Living With Excess Body Weight With or Without Type 2 Diabetes NNC0519-0130, Placebo - Diabetes Mellitus, Type 2, Obesity Phase 1 Completed 82 2024-08-07 2025-12-31
A Research Study Looking Into the Effect of NNC0519-0130 on Blood Levels of a Birth Control Pill and Emptying of the Stomach in Women After Menopause NNC0519-0130, Levonorgestrel + Ethinylestradiol, Paracetamol - Diabetes Mellitus, Type 2 Phase 1 Completed 47 2024-07-18 2026-03-12
A Research Study Looking Into Blood Levels of the Medicine NNC0519-0130 in the Body in Participants With Normal or Reduced Kidney Function NNC0519-0130 - Diabetes Mellitus, Type 2 Phase 1 Completed 36 2024-04-15 2026-04-07
A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose Weight NNC0519-0130, Placebo, Tirzepatide - Obesity Phase 2 Completed 354 2024-03-18 2026-04-15
A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes NNC0519-0130, Placebo, Trizepatide - Diabetes Mellitus, Type 2 Phase 2 Completed 299 2024-03-18 2026-09-21
A Research Study of a New Medicine NNC0519-0130 in Japanese and Non-Japanese Men NNC0519-0130, Placebo - Diabetes Mellitus, Type 2 Phase 1 Completed 22 2023-05-15 2025-06-18
A Research Study of a New Medicine NNC0519-0130 in Healthy People, People With High Body Weight and People With Type 2 Diabetes. NNC0519-0130, Placebo (NNC0519-0130) - Healthy Volunteers (Diabetes Mellitus, Type 2) Phase 1 Completed 161 2022-04-20 2025-12-31
Conditions studied Diabetes Mellitus, Type 2 (6) · Obesity (4) · Diabetes Mellitus (1) · Renal Insufficiency, Chronic (1)
Sponsors Novo Nordisk A/S (10)
Countries Germany (4) · Japan (4) · Australia (3) · United States (3) · India (2) · South Korea (2) · Argentina (1) · Austria (1) · Brazil (1) · Bulgaria (1) · Canada (1) · China (1) · Czechia (1) · Denmark (1) · Italy (1)
NIH funding 2023 (3)